CV Science

Jean-Marie Pagès Research director (DR1)

Course and current status

Version:1.0 StartHTML:0000000186 EndHTML:0000017340 StartFragment:0000006047 EndFragment:0000017304 SourceURL:file://localhost/BIOCIDES-SCENIHR/Candidat%202011/CV-JMPages-2011.doc

Education/Academic degrees

• PhD Microbiology Biochemistry (Immunochemistry of Alkaline Phosphatase), 1975, Université de Provence, Marseille, France
• Doctorat Es-Sciences (Study of the Biogenesis of E. coli Envelope), 1983, Université de la Méditerranée, Marseille, France

Position and employment

• 2000, Head of University team EA 2197
• 2006, Head of UMR-MD1, (Unité Mixte de Recherche Ministère de l’Enseignement Supérieur et de la Recherche et Ministère de la Défense) (Joint research Unit).
• 2008, Head of UMR-MD1 Research Unit« Membrane Transporters, Chemoresistance and Drug design »
• 2009, Senior Director of Research (DR1) INSERM
• 2012, Head of UMR-MD1 Research Unit« Membrane Transporters, Chemoresistance and Drug design »

Scientific Committee and expertises

• Member of Marie Curie RTN-CT-2005–019335 « Molecular basis of antibiotic translocation »
• Member of Scientific Committee on Emerging and Newly Identified Health Risks, SCENIHR (EC. DG SANCO) http://ec.europa.eu/health/scientific_committees/emerging/index_en.htm
• Expert for 7^th PCRDT de la Commission Européenne
• Expert for National Science Foundation (NSF-USA), Singapour-National Medical Research Council, United States - Israel Binational Agricultural Research & Development Fund

European research network, French research network

• Chairman of COST Action BM0701 « Antibiotic transport and efflux: New strategies to combat bacterial resistance »
• Member of French-ANR program « Metallodrugs with antibacterial activity : from synthesis to in situ biological activity »
• Coordinator of French-ANR program « Inhibitors for Bacterial Efflux Pumps »

Science Societies

• Member of American Society for Microbiology and Société Française de Microbiologie
• Referee for scientific journals: Nature Med., J. Mol. Biol., Mol. Microbiol, J. Bacteriol., Antimicrob. Agents Chemother., Biochem. J., etc

Honors

• Astra/Zeneca/ESMID Wall of resistance Research Grant 2002 “An analysis of in vivo activity of efflux pump inhibitors in antibiotic-resistant Enterobacter aerogenes”
• Eloi Collery Prix, Académie Nationale de Médecine, France 2005, “Bacterial membrane and antibiotic resistance mechanisms
• Honnor Medal of Service de Santé des Armées (Health Dept. of French Army), 2010.

Scientific summary

Version:1.0 StartHTML:0000000186 EndHTML:0000005834 StartFragment:0000003759 EndFragment:0000005798 SourceURL:file://localhost/BIOCIDES-SCENIHR/Candidat%202011/CV-JMPages-2011.doc

Present Research Interest

• Bacterial membrane transporters (genetic, structural and functional aspects, structural-activity relationship)
• Antibiotic resistance mechanisms in bacteria, e.g. mechanism-biochemistry, epidemiology, regulation and expression, activity and clinical involvement, assessment of risk factors associated with the emerging resistance mechanism
• Drug efflux pumps involved in antibiotic resistance (regulation, activity, etc)
• New antimicrobial compounds, new antibacterial activity or molecules that target resistance mechanism (inhibitor of efflux pumps)

Publications and scientif productions

over 250 scientific publications, abstracts, lectures and communications in bacteriology-biochemistry-chemistry field, several chapters in academic books; patents concerning bacterial membranes and new molecules

Five recent publications (2008-2011) in the field:

• Pagès J.-M., et al. 2008 The porin and the permeating molecule: a selective diffusion barrier in Gram-negative bacteria. Nature Reviews Microbiology, 6: 893-903.
• Mamelli L, et al. New antibiotic molecules: bypassing the membrane barrier of gram negative bacteria increases the activity of peptide deformylase inhibitors. PLoS One. 2009, 4: e6443.
• Kuete V., et al. 2010. Efflux pumps are involved in the Gram negative bacterial defense against isobavachalcone and diospyrone, two natural products. Antimicrob. Agents Chemother., 54: 1749-52.
• Tran QT, et al. 2010 Functional approach of porin channel: Antibiotic pathway through Providencia porins. J. Biol. Chem., 285: 32273-81.
• Nikaido H and Pagès JM. 2011. Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria. FEMS Microbiol. Rev. in press doi: 10.1111/j.1574-6976.2011.00290.x.

Five recent lectures in the field:

• Pagès J.-M. Bacterial transporters: the Pandora box of antibiotic resistance, 462nd WE Heraeus Seminar and BM0701 5th MCM-WG meeting, Bremen, Germany, 2010.
• Pagès J.-M. QSAR for blocking bacterial efflux pumps. ESF Exploratory Workshop « Multi-disciplinary consorium for the development of effective, but non-toxic drugs against MDR-TB and XDR-TB » , Lisbon, Portugal, 2010.
• Pagès J.-M. « Modulation of membrane permeability: an efficient response to stress”. 21^st ECCMID-ICC, Milan, Italy, 2011.
• Pagès J.-M. « Bypass the membrane barrier strategy in multidrug resistant Gram-negative bacteria ». 36th FEBS, Turin, Italy, 2011.
• Pagès J.-M. Strategies for bypassing the membrane barrier in mmultidrug resistant Gram-negative organisms” AstraZeneca Infection IMED Annual Infection Symposium. Waltham,Boston, US, 2011.(Innovative Medicine Unit)

Recent scientific reports in the field as member of SCENIHR:

• Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) Opinion on: Assessment of the Antibiotic Resistance Effects of Biocides. Adopted by the SCENIHR during the 28th plenary meeting of 19 January 2009.
• Joint Opinion on antimicrobial resistance (AMR) focused on zoonotic infections. EFSA, the European Centre for Disease Prevention and Control, the European Medicines Agency and the European Commission’s Scientific Committee on Emerging and Newly Identified Health Risks published a joint scientific opinion on antimicrobial resistance focused on infections transmitted to humans from animals and food . EFSA-Q-2008-781 http://www.efsa.europa.eu/en/scdocs/scdoc/1372.htm Adopted: 28 October 2009.
• Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) Opinion on: Research strategy to address the knowledge gaps on the antimicrobial resistance effects of biocides . Adopted by the SCENIHR during the 7th plenary meeting of 17 March 2010